<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915016</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 108</org_study_id>
    <secondary_id>12007</secondary_id>
    <nct_id>NCT02915016</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults</brief_title>
  <official_title>A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in&#xD;
      combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent&#xD;
      Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immune response of the&#xD;
      DNA-HIV-PT123 vaccine when used in combination with one of two protein vaccines: Bivalent&#xD;
      Subtype C gp120/MF59 (Protein/MF59) or Bivalent Subtype C gp120/AS01B (Protein/AS01B). These&#xD;
      protein vaccines may boost the immune response to the DNA vaccine.&#xD;
&#xD;
      The study will enroll healthy, HIV-uninfected adults. Participants will be randomly assigned&#xD;
      to one of eight groups, and each group will receive a different sequence of vaccines during&#xD;
      the study. Groups 1 and 4 will receive the DNA-HIV-PT123 vaccine, the Protein/MF59 vaccine,&#xD;
      and placebo. Groups 2, 3, 5, 6, and 7 will receive the DNA-HIV-PT123 vaccine, the&#xD;
      Protein/AS01B vaccine, and placebo. Group 8 will only receive placebo.&#xD;
&#xD;
      All participants will receive their assigned vaccines at Months 0, 1, 3, and 6. Each of these&#xD;
      visits will include three injections. Follow-up visits will occur at Week 2 and Months 1.5,&#xD;
      3.5, 6.25, 6.5, 9, and 12.&#xD;
&#xD;
      Study visits will include a physical examination, an interview and/or questionnaire, HIV&#xD;
      testing and HIV risk reduction counseling, and urine and blood collection. Participants may&#xD;
      optionally choose to provide stool, rectal fluid, cervical fluid, or semen samples.&#xD;
      Participants will be contacted 6 months after the last scheduled visit by phone, text&#xD;
      message, or e-mail for information about their health.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness</measure>
    <time_frame>Measured through 7 days after each vaccine dose at Month 0, 1, 3, and 6</time_frame>
    <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The maximum grade observed for each symptom over the time frame is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration</measure>
    <time_frame>Measured through 7 days after each vaccine dose at Month 0, 1, 3, and 6</time_frame>
    <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The maximum grade observed for each symptom over the time frame is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms</measure>
    <time_frame>Measured through 7 days after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Reaction is the maximum of the individual systemic variables for a participant. It does not include temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events (AEs), by Relationship to Study Product</measure>
    <time_frame>Measured through 30 days after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For participants reporting multiple AEs over the time frame, the maximum relationship is counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events (AEs), by Severity Grade</measure>
    <time_frame>Measured through 30 days after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For participants reporting multiple AEs over the time frame, the maximum severity grade is counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>Measured as outlined in Version 2.0 (January 2010) of the Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Measured through Month 18</time_frame>
    <description>There were no adverse events of special interest reported by any participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting New Chronic Conditions (Requiring Medical Intervention for ≥ 30 Days)</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>There were no new chronic conditions (requiring medical intervention for ≥ 30 days) reported by any participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Early Study Termination Associated With an AE or Reactogenicity</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>There were no early study terminations associated with an AE or reactogenicity reported by any participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Study Product Discontinuation Associated With an AE or Reactogenicity</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>From the study product discontinuation form, study product administration reasons are tabulated by treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemistry and Hematology Laboratory Measures - ALT(SGPT), AST, Alkaline Phosphatase.</measure>
    <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemistry and Hematology Laboratory Measures - Creatinine.</measure>
    <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemistry and Hematology Laboratory Measures - Hemoglobin.</measure>
    <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemistry and Hematology Laboratory Measures - Lymphocytes, Neutrophils.</measure>
    <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemistry and Hematology Laboratory Measures - Platelets, WBC.</measure>
    <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of Participants With Grade 1 or Higher Local Laboratory Results.</measure>
    <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
    <description>The numbers (percentages) of participants with local laboratory values recorded as meeting Grade 1 AE criteria or above as specified in the DAIDS AE Grading Table were tabulated by treatment group for each post vaccination timepoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Positive Response Rates.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>IgG binding antibody breadth assays were not run. Instead, IgG was assayed against a smaller panel of antigens. Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Magnitudes.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>IgG binding antibody breadth assays were not run. Instead, IgG was assayed against a smaller panel of antigens.Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Responses - Positive Response Rates.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Response - Magnitudes.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of Neutralizing Antibody Responses Against HIV-1 Isolates.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>The neutralizing antibody assay was not run. Therefore this dataset doesn't exist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of HIV-specific CD4+ T-cell Responses - Positive Response Rates.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of HIV-specific CD4+ T-cell Responses - Magnitudes.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of HIV-specific CD8+ T-cell Responses - Positive Response Rates.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and Level of HIV-specific CD8+ T-cell Responses - Magnitudes.</measure>
    <time_frame>Measured at Month 6.5</time_frame>
    <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: Placebo + Protein/AS01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA-HIV-PT123 vaccine</intervention_name>
    <description>Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.</description>
    <arm_group_label>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_label>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_label>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent Subtype C gp120/MF59 vaccine</intervention_name>
    <description>Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.</description>
    <arm_group_label>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_label>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <other_name>Protein/MF59 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent Subtype C gp120/AS01B vaccine</intervention_name>
    <description>Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.</description>
    <arm_group_label>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 7: Placebo + Protein/AS01B</arm_group_label>
    <other_name>Protein/AS01B vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
    <arm_group_label>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_label>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</arm_group_label>
    <arm_group_label>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 7: Placebo + Protein/AS01B</arm_group_label>
    <arm_group_label>Group 8: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General and Demographic Criteria&#xD;
&#xD;
          -  Age of 18 to 40 years&#xD;
&#xD;
          -  Access to a participating HVTN clinical research site (CRS) and willingness to be&#xD;
             followed for the planned duration of the study&#xD;
&#xD;
          -  Ability and willingness to provide informed consent&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study;&#xD;
             completes a questionnaire prior to first vaccination with verbal demonstration of&#xD;
             understanding of all questionnaire items answered incorrectly&#xD;
&#xD;
          -  Agrees not to enroll in another study of an investigational research agent before the&#xD;
             last required protocol clinic visit&#xD;
&#xD;
          -  Willing to be contacted by phone, text message, or e-mail 6 months after completion of&#xD;
             the scheduled clinic visits&#xD;
&#xD;
          -  Good general health as shown by medical history, physical exam, and screening&#xD;
             laboratory tests&#xD;
&#xD;
        HIV-Related Criteria:&#xD;
&#xD;
          -  Willingness to receive HIV test results&#xD;
&#xD;
          -  Willingness to discuss HIV infection risks and amenable to HIV risk reduction&#xD;
             counseling.&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection and committed to&#xD;
             maintaining behavior consistent with low risk of HIV exposure through the last&#xD;
             required protocol clinic visit.&#xD;
&#xD;
        Laboratory Inclusion Values:&#xD;
&#xD;
        Hemogram/Complete Blood Count (CBC)&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were born female,&#xD;
             greater than or equal to 13.0 g/dL for volunteers who were born male&#xD;
&#xD;
          -  White blood cell count equal to 3,300 to 12,000 cells/mm^3&#xD;
&#xD;
          -  Total lymphocyte count greater than or equal to 800 cells/mm^3&#xD;
&#xD;
          -  Remaining differential either within institutional normal range or with site physician&#xD;
             approval&#xD;
&#xD;
          -  Platelets equal to 125,000 to 550,000/mm^3&#xD;
&#xD;
        Chemistry&#xD;
&#xD;
          -  Chemistry panel: ALT, AST, and alkaline phosphatase less than 1.25 times the&#xD;
             institutional upper limit of normal; creatinine less than or equal to institutional&#xD;
             upper limit of normal.&#xD;
&#xD;
        Virology&#xD;
&#xD;
          -  Negative HIV-1 and -2 blood test: US volunteers must have a negative FDA-approved&#xD;
             enzyme immunoassay (EIA). Non-US sites may use locally available assays that have been&#xD;
             approved by HVTN Laboratory Operations.&#xD;
&#xD;
          -  Negative Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase&#xD;
             chain reaction (PCR) if the anti-HCV is positive&#xD;
&#xD;
        Urine&#xD;
&#xD;
          -  Normal urine:&#xD;
&#xD;
               -  Negative urine glucose, and&#xD;
&#xD;
               -  Negative or trace urine protein, and&#xD;
&#xD;
               -  Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a&#xD;
                  microscopic urinalysis with red blood cells levels within institutional normal&#xD;
                  range).&#xD;
&#xD;
        Reproductive Status&#xD;
&#xD;
          -  Volunteers who were born female: negative serum or urine beta human chorionic&#xD;
             gonadotropin (β-HCG) pregnancy test performed prior to vaccination on the day of&#xD;
             initial vaccination. Persons who are NOT of reproductive potential due to having&#xD;
             undergone total hysterectomy or bilateral oophorectomy (verified by medical records),&#xD;
             are not required to undergo pregnancy testing.&#xD;
&#xD;
        Reproductive status:&#xD;
&#xD;
        United States&#xD;
&#xD;
        A volunteer who was born female must:&#xD;
&#xD;
          -  Agree to consistently use effective contraception (see the protocol for more&#xD;
             information) for sexual activity that could lead to pregnancy from at least 21 days&#xD;
             prior to enrollment through the last required protocol clinic visit. Effective&#xD;
             contraception for participants in the United States is defined as using any 1 or more&#xD;
             of the following methods:&#xD;
&#xD;
               -  Condoms (male or female) with or without a spermicide,&#xD;
&#xD;
               -  Diaphragm or cervical cap with spermicide,&#xD;
&#xD;
               -  Intrauterine device (IUD),&#xD;
&#xD;
               -  Hormonal contraception, or&#xD;
&#xD;
               -  Successful vasectomy in the male partner (considered successful if a volunteer&#xD;
                  reports that a male partner has [1] documentation of azoospermia by microscopy,&#xD;
                  or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite&#xD;
                  sexual activity postvasectomy), or&#xD;
&#xD;
               -  Any other contraceptive method approved by the HVTN 108 protocol safety review&#xD;
                  team (PSRT)&#xD;
&#xD;
          -  Or not be of reproductive potential, such as having reached menopause (no menses for 1&#xD;
             year) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation;&#xD;
&#xD;
          -  Or be sexually abstinent.&#xD;
&#xD;
        Southern Africa&#xD;
&#xD;
        A volunteer who was born female must:&#xD;
&#xD;
          -  Agree to consistently use effective contraception (see the protocol for more&#xD;
             information) for sexual activity that could lead to pregnancy from at least 21 days&#xD;
             prior to enrollment through the last required protocol clinic visit. Effective&#xD;
             contraception for participants in Southern Africa is defined as using 2 methods of&#xD;
             birth control. These include 1 of the following methods:&#xD;
&#xD;
               -  Condoms (male or female)&#xD;
&#xD;
               -  Diaphragm or cervical cap&#xD;
&#xD;
          -  PLUS 1 of the following methods:&#xD;
&#xD;
               -  IUD,&#xD;
&#xD;
               -  Hormonal contraception (in accordance with applicable national contraception&#xD;
                  guidelines), or&#xD;
&#xD;
               -  Successful vasectomy in the male partner (considered successful if a volunteer&#xD;
                  reports that a male partner has [1] documentation of azoospermia by microscopy,&#xD;
                  or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite&#xD;
                  sexual activity postvasectomy), or&#xD;
&#xD;
               -  Any other contraceptive method approved by the HVTN 108 PSRT&#xD;
&#xD;
          -  Or not be of reproductive potential, such as having reached menopause (no menses for 1&#xD;
             year) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation;&#xD;
&#xD;
          -  Or be sexually abstinent.&#xD;
&#xD;
          -  Volunteers who were born female must also agree not to seek pregnancy through&#xD;
             alternative methods, such as artificial insemination or in vitro fertilization until&#xD;
             after the last required protocol clinic visit&#xD;
&#xD;
        Other&#xD;
&#xD;
        Volunteers 21 years of age and older who were born female consenting to provide cervical&#xD;
        samples:&#xD;
&#xD;
          -  Pap smear within:&#xD;
&#xD;
               -  the 3 years prior to enrollment with the latest result reported as normal or&#xD;
                  atypical squamous cells of undetermined significance (ASCUS), or&#xD;
&#xD;
               -  the 5 years prior to enrollment, with the latest result reported as normal, or&#xD;
                  ASCUS with no evidence of high risk human papillomavirus (HPV).&#xD;
&#xD;
          -  If no pap smear was done within the last 3 years (or within the last 5 years, if high&#xD;
             risk HPV testing was performed), the volunteer must be willing to undergo a pap smear&#xD;
             with the result reported as normal or ASCUS prior to sample collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Blood products received within 120 days before first vaccination&#xD;
&#xD;
          -  Investigational research agents received within 30 days before first vaccination&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 40; or BMI greater than or equal to 35&#xD;
             with 2 or more of the following: systolic blood pressure greater than 140 mm Hg,&#xD;
             diastolic blood pressure greater than 90 mm Hg, current smoker, known hyperlipidemia&#xD;
&#xD;
          -  Intent to participate in another study of an investigational research agent or any&#xD;
             other study that requires non-HVTN HIV antibody testing during the planned duration of&#xD;
             the HVTN 108 study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Active duty and reserve US military personnel&#xD;
&#xD;
        Vaccines and Other Injections&#xD;
&#xD;
          -  HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received&#xD;
             control/placebo in an HIV vaccine trial, the HVTN 108 PSRT will determine eligibility&#xD;
             on a case-by-case basis.&#xD;
&#xD;
          -  Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine&#xD;
             trial. Exceptions may be made for vaccines that have subsequently undergone licensure.&#xD;
             For volunteers who have received control/placebo in an experimental vaccine trial, the&#xD;
             HVTN 108 PSRT will determine eligibility on a case-by-case basis. For volunteers who&#xD;
             have received an experimental vaccine(s) greater than 5 years ago, eligibility for&#xD;
             enrollment will be determined by the HVTN 108 PSRT on a case-by-case basis.&#xD;
&#xD;
          -  Live attenuated vaccines other than influenza vaccine received within 30 days before&#xD;
             first vaccination or scheduled within 14 days after injection (eg, measles, mumps, and&#xD;
             rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever)&#xD;
&#xD;
          -  Influenza vaccine or any vaccines that are not live attenuated vaccines and were&#xD;
             received within 14 days prior to first vaccination (eg, tetanus, pneumococcal,&#xD;
             Hepatitis A or B)&#xD;
&#xD;
          -  Allergy treatment with antigen injections within 30 days before first vaccination or&#xD;
             that are scheduled within 14 days after first vaccination&#xD;
&#xD;
        Immune System&#xD;
&#xD;
          -  Immunosuppressive medications received within 168 days before first vaccination. (Not&#xD;
             exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical&#xD;
             corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of&#xD;
             oral/parenteral corticosteroids at doses less than 2 mg/kg/day and length of therapy&#xD;
             less than 11 days with completion at least 30 days prior to enrollment.)&#xD;
&#xD;
          -  Serious adverse reactions to vaccines or to vaccine components including history of&#xD;
             anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema,&#xD;
             and/or abdominal pain. (Not excluded from participation: a volunteer who had a&#xD;
             nonanaphylactic adverse reaction to pertussis vaccine as a child.)&#xD;
&#xD;
          -  Immunoglobulin received within 60 days before first vaccination&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
        Clinically significant medical conditions&#xD;
&#xD;
          -  Untreated or incompletely treated syphilis infection&#xD;
&#xD;
          -  Clinically significant medical condition, physical examination findings, clinically&#xD;
             significant abnormal laboratory results, or past medical history with clinically&#xD;
             significant implications for current health. A clinically significant condition or&#xD;
             process includes but is not limited to:&#xD;
&#xD;
               -  A process that would affect the immune response,&#xD;
&#xD;
               -  A process that would require medication that affects the immune response,&#xD;
&#xD;
               -  Any contraindication to repeated injections or blood draws,&#xD;
&#xD;
               -  A condition that requires active medical intervention or monitoring to avert&#xD;
                  grave danger to the volunteer's health or well-being during the study period,&#xD;
&#xD;
               -  A condition or process for which signs or symptoms could be confused with&#xD;
                  reactions to vaccine, or&#xD;
&#xD;
               -  Any condition specifically listed among the exclusion criteria below.&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence, assessment of safety or reactogenicity, or a volunteer's ability to give&#xD;
             informed consent&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#xD;
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,&#xD;
             or history of suicide attempt or gesture within the past 3 years.&#xD;
&#xD;
          -  Current anti-tuberculosis (TB) prophylaxis or therapy&#xD;
&#xD;
          -  Asthma other than mild, well-controlled asthma. (Symptoms of asthma severity as&#xD;
             defined in the most recent US National Asthma Education and Prevention Program (NAEPP)&#xD;
             Expert Panel report). Exclude a volunteer who:&#xD;
&#xD;
               -  Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or&#xD;
&#xD;
               -  Uses moderate/high dose inhaled corticosteroids, or&#xD;
&#xD;
               -  In the past year has either of the following:&#xD;
&#xD;
               -  Greater than 1 exacerbation of symptoms treated with oral/parenteral&#xD;
                  corticosteroids;&#xD;
&#xD;
               -  Needed emergency care, urgent care, hospitalization, or intubation for asthma.&#xD;
&#xD;
          -  Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not&#xD;
             excluded: history of isolated gestational diabetes.)&#xD;
&#xD;
          -  Thyroidectomy, or thyroid disease requiring medication during the last 12 months&#xD;
&#xD;
          -  Hypertension:&#xD;
&#xD;
               -  If a person has been found to have elevated blood pressure or hypertension during&#xD;
                  screening or previously, exclude for blood pressure that is not well controlled.&#xD;
                  Well-controlled blood pressure is defined as consistently less than or equal to&#xD;
                  140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or without&#xD;
                  medication, with only isolated, brief instances of higher readings, which must be&#xD;
                  less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg&#xD;
                  diastolic. For these volunteers, blood pressure must be less than or equal to 140&#xD;
                  mm Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment.&#xD;
&#xD;
               -  If a person has NOT been found to have elevated blood pressure or hypertension&#xD;
                  during screening or previously, exclude for systolic blood pressure greater than&#xD;
                  or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or&#xD;
                  equal to 100 mm Hg at enrollment.&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions)&#xD;
&#xD;
          -  Malignancy (Not excluded from participation: Volunteer who has had malignancy excised&#xD;
             surgically and who, in the investigator's estimation, has a reasonable assurance of&#xD;
             sustained cure, or who is unlikely to experience recurrence of malignancy during the&#xD;
             period of the study)&#xD;
&#xD;
          -  Seizure disorder: History of seizure(s) within past 3 years. Also exclude if volunteer&#xD;
             has used medications in order to prevent or treat seizure(s) at any time within the&#xD;
             past 3 years.&#xD;
&#xD;
          -  Asplenia: any condition resulting in the absence of a functional spleen&#xD;
&#xD;
          -  History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Garrett</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for the AIDS Programme of Research in South Africa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Vaccine CRS (BWH VCRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Health (FH) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-4302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Blood Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Vaccines to Prevent HIV Infection CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine (VV) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Vaccine and Prevention CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliptown Soweto CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1409</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Tembisa Clinical Research Centre CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto HVTN CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre CRS</name>
      <address>
        <city>Soshanguve</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAPRISA eThekwini CRS</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo Research Clinic CRS</name>
      <address>
        <city>Ladysmith</city>
        <state>Kwa Zulu Natal</state>
        <zip>3370</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verulam CRS</name>
      <address>
        <city>Verulam</city>
        <state>Kwa Zulu Natal</state>
        <zip>4340</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurum Institute Klerksdorp CRS</name>
      <address>
        <city>Klerksdorp</city>
        <state>North West Province</state>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emavundleni CRS</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7750</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02915016/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P6">
          <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P7">
          <title>Group 7: Placebo + Protein/AS01B</title>
          <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="P8">
          <title>Group 8: Placebo</title>
          <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 6.5 Immunogenicity Timepoint</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="42"/>
                <participants group_id="P8" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="38"/>
                <participants group_id="P8" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elected not to continue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HIV infection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant unable to adhere</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B6">
          <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B7">
          <title>Group 7: Placebo + Protein/AS01B</title>
          <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B8">
          <title>Group 8: Placebo</title>
          <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="50"/>
            <count group_id="B8" value="24"/>
            <count group_id="B9" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B2" value="25" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B3" value="25" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B4" value="24" lower_limit="18" upper_limit="38"/>
                    <measurement group_id="B5" value="27" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B6" value="25" lower_limit="18" upper_limit="38"/>
                    <measurement group_id="B7" value="25" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B8" value="26" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="B9" value="25" lower_limit="18" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Less than 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 - 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 - 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 - 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Sex assigned at birth</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="47"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="308"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness</title>
        <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The maximum grade observed for each symptom over the time frame is presented.</description>
        <time_frame>Measured through 7 days after each vaccine dose at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness</title>
          <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The maximum grade observed for each symptom over the time frame is presented.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Life Threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Life Threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain and/or Tenderness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Life Threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration</title>
        <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The maximum grade observed for each symptom over the time frame is presented.</description>
        <time_frame>Measured through 7 days after each vaccine dose at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration</title>
          <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The maximum grade observed for each symptom over the time frame is presented.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not gradable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Less than 5 cm diameter</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Between 6.25 to 25 cm sq area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Between 5 to 10 cm diameter</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Between 25 to 100 cm sq area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: Greater or equal to 10 cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: Greater or equal to 100 cm sq</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4: complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not gradable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Less than 5 cm diameter</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Between 6.25 to 25 cm sq area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Between 5 to 10 cm diameter</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Between 25 to 100 cm sq area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: Greater or equal to 10 cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: Greater or equal to 100 cm sq</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4: complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema and/or Induration</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not gradable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Less than 5 cm diameter</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Between 6.25 to 25 cm sq area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Between 5 to 10 cm diameter</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Between 25 to 100 cm sq area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: Greater or equal to 10 cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: Greater or equal to 100 cm sq</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4: complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms</title>
        <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Reaction is the maximum of the individual systemic variables for a participant. It does not include temperature.</description>
        <time_frame>Measured through 7 days after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms</title>
          <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Reaction is the maximum of the individual systemic variables for a participant. It does not include temperature.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Malaise and/or fatigue</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="45"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. Systemic Symptoms</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially Life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events (AEs), by Relationship to Study Product</title>
        <description>For participants reporting multiple AEs over the time frame, the maximum relationship is counted.</description>
        <time_frame>Measured through 30 days after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events (AEs), by Relationship to Study Product</title>
          <description>For participants reporting multiple AEs over the time frame, the maximum relationship is counted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No AE reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events (AEs), by Severity Grade</title>
        <description>For participants reporting multiple AEs over the time frame, the maximum severity grade is counted.</description>
        <time_frame>Measured through 30 days after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events (AEs), by Severity Grade</title>
          <description>For participants reporting multiple AEs over the time frame, the maximum severity grade is counted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No AE reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAEs)</title>
        <description>Measured as outlined in Version 2.0 (January 2010) of the Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual)</description>
        <time_frame>Measured through Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Serious Adverse Events (SAEs)</title>
          <description>Measured as outlined in Version 2.0 (January 2010) of the Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events of Special Interest (AESIs)</title>
        <description>There were no adverse events of special interest reported by any participant.</description>
        <time_frame>Measured through Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events of Special Interest (AESIs)</title>
          <description>There were no adverse events of special interest reported by any participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting New Chronic Conditions (Requiring Medical Intervention for ≥ 30 Days)</title>
        <description>There were no new chronic conditions (requiring medical intervention for ≥ 30 days) reported by any participant.</description>
        <time_frame>Measured through Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting New Chronic Conditions (Requiring Medical Intervention for ≥ 30 Days)</title>
          <description>There were no new chronic conditions (requiring medical intervention for ≥ 30 days) reported by any participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Early Study Termination Associated With an AE or Reactogenicity</title>
        <description>There were no early study terminations associated with an AE or reactogenicity reported by any participant.</description>
        <time_frame>Measured through Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Early Study Termination Associated With an AE or Reactogenicity</title>
          <description>There were no early study terminations associated with an AE or reactogenicity reported by any participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Study Product Discontinuation Associated With an AE or Reactogenicity</title>
        <description>From the study product discontinuation form, study product administration reasons are tabulated by treatment arm.</description>
        <time_frame>Measured through Month 6.5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Study Product Discontinuation Associated With an AE or Reactogenicity</title>
          <description>From the study product discontinuation form, study product administration reasons are tabulated by treatment arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinical event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Reactogenicity symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other reason</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Discontinuation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chemistry and Hematology Laboratory Measures - ALT(SGPT), AST, Alkaline Phosphatase.</title>
        <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
        <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemistry and Hematology Laboratory Measures - ALT(SGPT), AST, Alkaline Phosphatase.</title>
          <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT (SGPT) (U/L)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O2" value="14.5" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="O3" value="15" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O4" value="13.5" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="O5" value="16.5" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O6" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O7" value="15" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O8" value="17" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT) (U/L)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12.5" upper_limit="16.5"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O3" value="16" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O4" value="13" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O5" value="17.5" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O6" value="16" lower_limit="11" upper_limit="23.5"/>
                    <measurement group_id="O7" value="15.5" lower_limit="10" upper_limit="19.5"/>
                    <measurement group_id="O8" value="16" lower_limit="11" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT) (U/L)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O2" value="14" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O3" value="14" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O4" value="13" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="O5" value="16" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O6" value="16" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O7" value="15" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="O8" value="14" lower_limit="10" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT) (U/L)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12" upper_limit="17.5"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="O3" value="14.5" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O4" value="14" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O5" value="18" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="O6" value="17" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O7" value="15" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O8" value="16" lower_limit="12" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT) (U/L)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="22"/>
                    <measurement group_id="O3" value="14" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O4" value="16" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="O5" value="16" lower_limit="13" upper_limit="23.5"/>
                    <measurement group_id="O6" value="19.5" lower_limit="10" upper_limit="27"/>
                    <measurement group_id="O7" value="16" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O8" value="20" lower_limit="11" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="17" upper_limit="22"/>
                    <measurement group_id="O2" value="18.5" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O3" value="19" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O4" value="19" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O5" value="20" lower_limit="17" upper_limit="22"/>
                    <measurement group_id="O6" value="19" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O7" value="19.5" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O8" value="20" lower_limit="16.5" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="16.5" upper_limit="21"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O3" value="19" lower_limit="16" upper_limit="25"/>
                    <measurement group_id="O4" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O5" value="19.5" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O6" value="19.5" lower_limit="15" upper_limit="25"/>
                    <measurement group_id="O7" value="19" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O8" value="19" lower_limit="17" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="O2" value="19" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="O3" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O4" value="16.5" lower_limit="14" upper_limit="20.5"/>
                    <measurement group_id="O5" value="19" lower_limit="16" upper_limit="25"/>
                    <measurement group_id="O6" value="19" lower_limit="15" upper_limit="23"/>
                    <measurement group_id="O7" value="19" lower_limit="18" upper_limit="22"/>
                    <measurement group_id="O8" value="19" lower_limit="15" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="15.5" upper_limit="21"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="O3" value="18.5" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O4" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O5" value="20" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O6" value="20" lower_limit="16" upper_limit="26"/>
                    <measurement group_id="O7" value="18" lower_limit="15.5" upper_limit="22.5"/>
                    <measurement group_id="O8" value="20" lower_limit="18" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="15.5" upper_limit="21.5"/>
                    <measurement group_id="O2" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O3" value="19" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O4" value="18.5" lower_limit="16" upper_limit="26"/>
                    <measurement group_id="O5" value="19.5" lower_limit="17" upper_limit="23"/>
                    <measurement group_id="O6" value="21" lower_limit="17" upper_limit="27"/>
                    <measurement group_id="O7" value="19" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O8" value="23" lower_limit="18" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="47" upper_limit="71"/>
                    <measurement group_id="O2" value="72.5" lower_limit="60" upper_limit="89"/>
                    <measurement group_id="O3" value="70.5" lower_limit="59" upper_limit="88"/>
                    <measurement group_id="O4" value="70" lower_limit="54" upper_limit="78"/>
                    <measurement group_id="O5" value="69.5" lower_limit="54" upper_limit="80"/>
                    <measurement group_id="O6" value="70" lower_limit="55" upper_limit="83"/>
                    <measurement group_id="O7" value="66" lower_limit="58" upper_limit="85"/>
                    <measurement group_id="O8" value="59.5" lower_limit="55" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="45.5" upper_limit="68.5"/>
                    <measurement group_id="O2" value="67" lower_limit="56" upper_limit="84"/>
                    <measurement group_id="O3" value="62.5" lower_limit="53" upper_limit="89"/>
                    <measurement group_id="O4" value="65.5" lower_limit="49" upper_limit="76"/>
                    <measurement group_id="O5" value="64" lower_limit="53" upper_limit="80"/>
                    <measurement group_id="O6" value="68" lower_limit="55" upper_limit="81.5"/>
                    <measurement group_id="O7" value="63" lower_limit="51" upper_limit="77.5"/>
                    <measurement group_id="O8" value="65.5" lower_limit="50.5" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="48" upper_limit="68"/>
                    <measurement group_id="O2" value="67" lower_limit="57" upper_limit="78"/>
                    <measurement group_id="O3" value="67" lower_limit="55" upper_limit="84"/>
                    <measurement group_id="O4" value="64" lower_limit="51.5" upper_limit="77.5"/>
                    <measurement group_id="O5" value="62" lower_limit="54" upper_limit="81"/>
                    <measurement group_id="O6" value="68" lower_limit="56" upper_limit="79"/>
                    <measurement group_id="O7" value="65" lower_limit="51" upper_limit="76"/>
                    <measurement group_id="O8" value="67" lower_limit="57" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="47" upper_limit="69"/>
                    <measurement group_id="O2" value="64" lower_limit="60" upper_limit="78"/>
                    <measurement group_id="O3" value="65" lower_limit="56" upper_limit="84"/>
                    <measurement group_id="O4" value="63" lower_limit="52" upper_limit="75"/>
                    <measurement group_id="O5" value="62" lower_limit="52" upper_limit="78"/>
                    <measurement group_id="O6" value="68" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="O7" value="62" lower_limit="53" upper_limit="75"/>
                    <measurement group_id="O8" value="66.5" lower_limit="48" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="50" upper_limit="74.5"/>
                    <measurement group_id="O2" value="70" lower_limit="61" upper_limit="77"/>
                    <measurement group_id="O3" value="70" lower_limit="57" upper_limit="88"/>
                    <measurement group_id="O4" value="69" lower_limit="53" upper_limit="85"/>
                    <measurement group_id="O5" value="64.5" lower_limit="52" upper_limit="78"/>
                    <measurement group_id="O6" value="69.5" lower_limit="60" upper_limit="81"/>
                    <measurement group_id="O7" value="65" lower_limit="57" upper_limit="79"/>
                    <measurement group_id="O8" value="68" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chemistry and Hematology Laboratory Measures - Creatinine.</title>
        <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
        <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemistry and Hematology Laboratory Measures - Creatinine.</title>
          <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (mg/dL)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.795" lower_limit="0.7" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.7" upper_limit="0.91"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="0.89"/>
                    <measurement group_id="O4" value="0.79" lower_limit="0.7" upper_limit="0.91"/>
                    <measurement group_id="O5" value="0.77" lower_limit="0.67" upper_limit="0.87"/>
                    <measurement group_id="O6" value="0.715" lower_limit="0.62" upper_limit="0.87"/>
                    <measurement group_id="O7" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O8" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.785" lower_limit="0.685" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.65" upper_limit="0.95"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="0.87"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.77" upper_limit="0.95"/>
                    <measurement group_id="O5" value="0.78" lower_limit="0.65" upper_limit="0.9"/>
                    <measurement group_id="O6" value="0.79" lower_limit="0.7" upper_limit="0.88"/>
                    <measurement group_id="O7" value="0.8" lower_limit="0.7" upper_limit="0.915"/>
                    <measurement group_id="O8" value="0.805" lower_limit="0.7" upper_limit="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.71" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.7" upper_limit="0.95"/>
                    <measurement group_id="O3" value="0.805" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O4" value="0.81" lower_limit="0.77" upper_limit="0.9"/>
                    <measurement group_id="O5" value="0.8" lower_limit="0.7" upper_limit="0.89"/>
                    <measurement group_id="O6" value="0.79" lower_limit="0.63" upper_limit="0.9"/>
                    <measurement group_id="O7" value="0.8" lower_limit="0.7" upper_limit="0.93"/>
                    <measurement group_id="O8" value="0.84" lower_limit="0.72" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.815" lower_limit="0.72" upper_limit="0.905"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.695" upper_limit="0.945"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="0.94"/>
                    <measurement group_id="O4" value="0.81" lower_limit="0.72" upper_limit="0.91"/>
                    <measurement group_id="O5" value="0.78" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O6" value="0.79" lower_limit="0.7" upper_limit="0.81"/>
                    <measurement group_id="O7" value="0.83" lower_limit="0.7" upper_limit="0.95"/>
                    <measurement group_id="O8" value="0.9" lower_limit="0.75" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.7" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.855" lower_limit="0.72" upper_limit="0.98"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="0.93"/>
                    <measurement group_id="O4" value="0.84" lower_limit="0.76" upper_limit="0.98"/>
                    <measurement group_id="O5" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O6" value="0.785" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O7" value="0.84" lower_limit="0.7" upper_limit="1"/>
                    <measurement group_id="O8" value="0.87" lower_limit="0.8" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chemistry and Hematology Laboratory Measures - Hemoglobin.</title>
        <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
        <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemistry and Hematology Laboratory Measures - Hemoglobin.</title>
          <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin (g/dL)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.15" lower_limit="12.6" upper_limit="14.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="13.3" upper_limit="15.5"/>
                    <measurement group_id="O3" value="14.2" lower_limit="13" upper_limit="15.4"/>
                    <measurement group_id="O4" value="14.2" lower_limit="13.5" upper_limit="15.5"/>
                    <measurement group_id="O5" value="14.2" lower_limit="13.5" upper_limit="15.3"/>
                    <measurement group_id="O6" value="14.5" lower_limit="12.9" upper_limit="15.3"/>
                    <measurement group_id="O7" value="13.85" lower_limit="13.3" upper_limit="15.3"/>
                    <measurement group_id="O8" value="14.6" lower_limit="12.95" upper_limit="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="12.6" upper_limit="14.4"/>
                    <measurement group_id="O2" value="13.8" lower_limit="13.2" upper_limit="14.8"/>
                    <measurement group_id="O3" value="13.6" lower_limit="12.4" upper_limit="14.7"/>
                    <measurement group_id="O4" value="13.55" lower_limit="12.6" upper_limit="15"/>
                    <measurement group_id="O5" value="13.9" lower_limit="12.7" upper_limit="14.9"/>
                    <measurement group_id="O6" value="13.7" lower_limit="12.1" upper_limit="14.65"/>
                    <measurement group_id="O7" value="13.4" lower_limit="12.85" upper_limit="14.5"/>
                    <measurement group_id="O8" value="14.05" lower_limit="12.5" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="13" upper_limit="15.1"/>
                    <measurement group_id="O2" value="13.8" lower_limit="12.9" upper_limit="14.8"/>
                    <measurement group_id="O3" value="13.8" lower_limit="12.7" upper_limit="14.8"/>
                    <measurement group_id="O4" value="13.75" lower_limit="12.75" upper_limit="14.7"/>
                    <measurement group_id="O5" value="13.9" lower_limit="13.3" upper_limit="15.2"/>
                    <measurement group_id="O6" value="14" lower_limit="12.5" upper_limit="15"/>
                    <measurement group_id="O7" value="13.9" lower_limit="13" upper_limit="14.5"/>
                    <measurement group_id="O8" value="14" lower_limit="13.1" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="12.8" upper_limit="15.2"/>
                    <measurement group_id="O2" value="13.95" lower_limit="12.75" upper_limit="15.25"/>
                    <measurement group_id="O3" value="13.9" lower_limit="13.1" upper_limit="15"/>
                    <measurement group_id="O4" value="13.7" lower_limit="12.9" upper_limit="15.1"/>
                    <measurement group_id="O5" value="14.1" lower_limit="13.1" upper_limit="15.4"/>
                    <measurement group_id="O6" value="14.05" lower_limit="12.8" upper_limit="15"/>
                    <measurement group_id="O7" value="14" lower_limit="13.2" upper_limit="15"/>
                    <measurement group_id="O8" value="14.35" lower_limit="12.6" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" lower_limit="13.2" upper_limit="15.05"/>
                    <measurement group_id="O2" value="14" lower_limit="13.4" upper_limit="15.3"/>
                    <measurement group_id="O3" value="14.1" lower_limit="13.2" upper_limit="15.4"/>
                    <measurement group_id="O4" value="14" lower_limit="12.9" upper_limit="15.2"/>
                    <measurement group_id="O5" value="14.03" lower_limit="12.6" upper_limit="15"/>
                    <measurement group_id="O6" value="14.05" lower_limit="13" upper_limit="15"/>
                    <measurement group_id="O7" value="14.05" lower_limit="13.5" upper_limit="15"/>
                    <measurement group_id="O8" value="14.1" lower_limit="13.4" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chemistry and Hematology Laboratory Measures - Lymphocytes, Neutrophils.</title>
        <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
        <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemistry and Hematology Laboratory Measures - Lymphocytes, Neutrophils.</title>
          <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
          <units>cells/cubic mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophils (cells/cubic mm)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4060.5" lower_limit="2740" upper_limit="5069"/>
                    <measurement group_id="O2" value="3540" lower_limit="2870" upper_limit="4352"/>
                    <measurement group_id="O3" value="3108.5" lower_limit="2670" upper_limit="4498"/>
                    <measurement group_id="O4" value="3919" lower_limit="3280" upper_limit="4627"/>
                    <measurement group_id="O5" value="3616" lower_limit="2725" upper_limit="4718"/>
                    <measurement group_id="O6" value="3505" lower_limit="2719" upper_limit="4269"/>
                    <measurement group_id="O7" value="3389" lower_limit="2684" upper_limit="4397"/>
                    <measurement group_id="O8" value="3861" lower_limit="2953.5" upper_limit="4597.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (cells/cubic mm)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3156.5" lower_limit="2499" upper_limit="4400.5"/>
                    <measurement group_id="O2" value="3230" lower_limit="2437" upper_limit="3830"/>
                    <measurement group_id="O3" value="3404" lower_limit="2353" upper_limit="4158"/>
                    <measurement group_id="O4" value="3108" lower_limit="2717" upper_limit="4623"/>
                    <measurement group_id="O5" value="3910" lower_limit="2614" upper_limit="4854"/>
                    <measurement group_id="O6" value="3874" lower_limit="2840.5" upper_limit="5127.5"/>
                    <measurement group_id="O7" value="3420" lower_limit="2535" upper_limit="4515.5"/>
                    <measurement group_id="O8" value="3366.5" lower_limit="2682" upper_limit="5314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (cells/cubic mm)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3149" lower_limit="2840" upper_limit="4349"/>
                    <measurement group_id="O2" value="2795" lower_limit="2255.5" upper_limit="4220"/>
                    <measurement group_id="O3" value="3300" lower_limit="2448" upper_limit="4250"/>
                    <measurement group_id="O4" value="3467.5" lower_limit="2790" upper_limit="4144"/>
                    <measurement group_id="O5" value="3440" lower_limit="2773" upper_limit="4370"/>
                    <measurement group_id="O6" value="3580" lower_limit="2740" upper_limit="4370"/>
                    <measurement group_id="O7" value="3630" lower_limit="2805" upper_limit="4678"/>
                    <measurement group_id="O8" value="3532" lower_limit="2729" upper_limit="4910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (cells/cubic mm)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2980" lower_limit="2310" upper_limit="4002"/>
                    <measurement group_id="O2" value="2969" lower_limit="2272" upper_limit="3763.5"/>
                    <measurement group_id="O3" value="3602.5" lower_limit="2622" upper_limit="4310"/>
                    <measurement group_id="O4" value="3805" lower_limit="3103" upper_limit="4540"/>
                    <measurement group_id="O5" value="3519" lower_limit="2904" upper_limit="4193"/>
                    <measurement group_id="O6" value="3331.5" lower_limit="2730" upper_limit="4482"/>
                    <measurement group_id="O7" value="3345" lower_limit="2542" upper_limit="3928"/>
                    <measurement group_id="O8" value="3433" lower_limit="2656" upper_limit="4110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (cells/cubic mm)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3061" lower_limit="2815.5" upper_limit="4376.5"/>
                    <measurement group_id="O2" value="3259" lower_limit="2562" upper_limit="4132"/>
                    <measurement group_id="O3" value="3311" lower_limit="2636" upper_limit="4534"/>
                    <measurement group_id="O4" value="3508.5" lower_limit="2754" upper_limit="4863"/>
                    <measurement group_id="O5" value="3616" lower_limit="2840" upper_limit="4863"/>
                    <measurement group_id="O6" value="3395" lower_limit="2758" upper_limit="4190"/>
                    <measurement group_id="O7" value="3794.5" lower_limit="2897" upper_limit="5210"/>
                    <measurement group_id="O8" value="3370" lower_limit="2738" upper_limit="3926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (cells/cubic mm)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2033" lower_limit="1660" upper_limit="2590"/>
                    <measurement group_id="O2" value="1906" lower_limit="1670" upper_limit="2470"/>
                    <measurement group_id="O3" value="2044.5" lower_limit="1730" upper_limit="2405"/>
                    <measurement group_id="O4" value="1993.5" lower_limit="1610" upper_limit="2310"/>
                    <measurement group_id="O5" value="2054.5" lower_limit="1550" upper_limit="2412"/>
                    <measurement group_id="O6" value="2002.5" lower_limit="1740" upper_limit="2384"/>
                    <measurement group_id="O7" value="1942" lower_limit="1570" upper_limit="2270"/>
                    <measurement group_id="O8" value="2150" lower_limit="1940.5" upper_limit="2796.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (cells/cubic mm)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1963.5" lower_limit="1578" upper_limit="2269.5"/>
                    <measurement group_id="O2" value="1953" lower_limit="1587" upper_limit="2469"/>
                    <measurement group_id="O3" value="1936" lower_limit="1593" upper_limit="2283"/>
                    <measurement group_id="O4" value="1965" lower_limit="1699" upper_limit="2440"/>
                    <measurement group_id="O5" value="1857" lower_limit="1600" upper_limit="2356"/>
                    <measurement group_id="O6" value="2014.5" lower_limit="1621" upper_limit="2303"/>
                    <measurement group_id="O7" value="1746.5" lower_limit="1540" upper_limit="2138"/>
                    <measurement group_id="O8" value="2030.5" lower_limit="1891" upper_limit="2296.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (cells/cubic mm)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1881.5" lower_limit="1611" upper_limit="2150"/>
                    <measurement group_id="O2" value="1794" lower_limit="1430" upper_limit="2488"/>
                    <measurement group_id="O3" value="1972" lower_limit="1681" upper_limit="2320"/>
                    <measurement group_id="O4" value="1944" lower_limit="1720" upper_limit="2465"/>
                    <measurement group_id="O5" value="2060" lower_limit="1784" upper_limit="2640"/>
                    <measurement group_id="O6" value="1990" lower_limit="1752" upper_limit="2267"/>
                    <measurement group_id="O7" value="1910" lower_limit="1556" upper_limit="2400"/>
                    <measurement group_id="O8" value="2008" lower_limit="1650" upper_limit="2450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (cells/cubic mm)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1859" lower_limit="1570" upper_limit="2111"/>
                    <measurement group_id="O2" value="1920.5" lower_limit="1599.5" upper_limit="2135.5"/>
                    <measurement group_id="O3" value="2010" lower_limit="1722" upper_limit="2332"/>
                    <measurement group_id="O4" value="2035" lower_limit="1651" upper_limit="2550"/>
                    <measurement group_id="O5" value="2003" lower_limit="1660" upper_limit="2330"/>
                    <measurement group_id="O6" value="1907.5" lower_limit="1653" upper_limit="2180"/>
                    <measurement group_id="O7" value="1863" lower_limit="1640" upper_limit="2230"/>
                    <measurement group_id="O8" value="2198" lower_limit="1922" upper_limit="2613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (cells/cubic mm)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1868" lower_limit="1385" upper_limit="2175"/>
                    <measurement group_id="O2" value="1887" lower_limit="1590" upper_limit="2309"/>
                    <measurement group_id="O3" value="1848.5" lower_limit="1550" upper_limit="2264"/>
                    <measurement group_id="O4" value="2090.5" lower_limit="1566" upper_limit="2400"/>
                    <measurement group_id="O5" value="1990" lower_limit="1810" upper_limit="2570"/>
                    <measurement group_id="O6" value="2066.5" lower_limit="1683" upper_limit="2310"/>
                    <measurement group_id="O7" value="1795" lower_limit="1522" upper_limit="2291"/>
                    <measurement group_id="O8" value="1962" lower_limit="1806.5" upper_limit="2569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chemistry and Hematology Laboratory Measures - Platelets, WBC.</title>
        <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
        <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemistry and Hematology Laboratory Measures - Platelets, WBC.</title>
          <description>For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.</description>
          <units>x1000/cubic mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WBC (x1000/cubic mm)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" lower_limit="5.57" upper_limit="8.27"/>
                    <measurement group_id="O2" value="6.45" lower_limit="5.3" upper_limit="7.32"/>
                    <measurement group_id="O3" value="5.94" lower_limit="4.92" upper_limit="7.87"/>
                    <measurement group_id="O4" value="6.665" lower_limit="5.72" upper_limit="7.2"/>
                    <measurement group_id="O5" value="6.35" lower_limit="5.17" upper_limit="7.6"/>
                    <measurement group_id="O6" value="5.94" lower_limit="5.17" upper_limit="7.66"/>
                    <measurement group_id="O7" value="6.17" lower_limit="5.3" upper_limit="6.81"/>
                    <measurement group_id="O8" value="7.135" lower_limit="5.705" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC (x1000/cubic mm)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.705" lower_limit="5.06" upper_limit="6.905"/>
                    <measurement group_id="O2" value="6.04" lower_limit="4.68" upper_limit="7.1"/>
                    <measurement group_id="O3" value="5.795" lower_limit="4.64" upper_limit="6.86"/>
                    <measurement group_id="O4" value="6.155" lower_limit="5.05" upper_limit="6.9"/>
                    <measurement group_id="O5" value="6.41" lower_limit="4.96" upper_limit="7.85"/>
                    <measurement group_id="O6" value="6.25" lower_limit="5.25" upper_limit="8.225"/>
                    <measurement group_id="O7" value="6" lower_limit="5.11" upper_limit="7.17"/>
                    <measurement group_id="O8" value="6.36" lower_limit="5.37" upper_limit="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC (x1000/cubic mm)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.815" lower_limit="5" upper_limit="7.24"/>
                    <measurement group_id="O2" value="5.55" lower_limit="4.6" upper_limit="7.1"/>
                    <measurement group_id="O3" value="6" lower_limit="4.68" upper_limit="7.2"/>
                    <measurement group_id="O4" value="6.04" lower_limit="5.265" upper_limit="7.4"/>
                    <measurement group_id="O5" value="6.25" lower_limit="5.3" upper_limit="7.63"/>
                    <measurement group_id="O6" value="6.4" lower_limit="5.34" upper_limit="7.26"/>
                    <measurement group_id="O7" value="6.09" lower_limit="5.38" upper_limit="7.4"/>
                    <measurement group_id="O8" value="6.9" lower_limit="5.2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC (x1000/cubic mm)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="4.56" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.69" lower_limit="4.635" upper_limit="6.705"/>
                    <measurement group_id="O3" value="5.985" lower_limit="5.02" upper_limit="7.34"/>
                    <measurement group_id="O4" value="6.68" lower_limit="5.91" upper_limit="7.48"/>
                    <measurement group_id="O5" value="6.22" lower_limit="5.02" upper_limit="7.3"/>
                    <measurement group_id="O6" value="6.075" lower_limit="5.28" upper_limit="7.24"/>
                    <measurement group_id="O7" value="5.8" lower_limit="5.2" upper_limit="6.9"/>
                    <measurement group_id="O8" value="6.41" lower_limit="5.4" upper_limit="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC (x1000/cubic mm)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="4.875" upper_limit="7.345"/>
                    <measurement group_id="O2" value="6.29" lower_limit="5" upper_limit="7.4"/>
                    <measurement group_id="O3" value="5.515" lower_limit="5.1" upper_limit="7.36"/>
                    <measurement group_id="O4" value="6.46" lower_limit="5.31" upper_limit="7.6"/>
                    <measurement group_id="O5" value="6.39" lower_limit="5.44" upper_limit="7.6"/>
                    <measurement group_id="O6" value="5.9" lower_limit="5.31" upper_limit="7.35"/>
                    <measurement group_id="O7" value="6.585" lower_limit="5.5" upper_limit="7.54"/>
                    <measurement group_id="O8" value="5.835" lower_limit="5.31" upper_limit="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x1000/cubic mm)-Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.5" lower_limit="199" upper_limit="311"/>
                    <measurement group_id="O2" value="243" lower_limit="216" upper_limit="296"/>
                    <measurement group_id="O3" value="269.5" lower_limit="226" upper_limit="304"/>
                    <measurement group_id="O4" value="258" lower_limit="228" upper_limit="291"/>
                    <measurement group_id="O5" value="275" lower_limit="225" upper_limit="314"/>
                    <measurement group_id="O6" value="280" lower_limit="240" upper_limit="303"/>
                    <measurement group_id="O7" value="264.5" lower_limit="238" upper_limit="288"/>
                    <measurement group_id="O8" value="252.5" lower_limit="226.5" upper_limit="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x1000/cubic mm)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.5" lower_limit="201.5" upper_limit="281.5"/>
                    <measurement group_id="O2" value="236" lower_limit="215" upper_limit="299"/>
                    <measurement group_id="O3" value="264.5" lower_limit="218.4" upper_limit="311"/>
                    <measurement group_id="O4" value="255.15" lower_limit="233" upper_limit="291"/>
                    <measurement group_id="O5" value="285" lower_limit="245" upper_limit="318"/>
                    <measurement group_id="O6" value="279.5" lower_limit="249" upper_limit="318.5"/>
                    <measurement group_id="O7" value="284" lower_limit="249" upper_limit="310.5"/>
                    <measurement group_id="O8" value="257.5" lower_limit="230" upper_limit="289.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x1000/cubic mm)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.5" lower_limit="206.6" upper_limit="282"/>
                    <measurement group_id="O2" value="241" lower_limit="210" upper_limit="285"/>
                    <measurement group_id="O3" value="264" lower_limit="204" upper_limit="303"/>
                    <measurement group_id="O4" value="258.95" lower_limit="242" upper_limit="310.85"/>
                    <measurement group_id="O5" value="292" lower_limit="250" upper_limit="331"/>
                    <measurement group_id="O6" value="288" lower_limit="247" upper_limit="320"/>
                    <measurement group_id="O7" value="286" lower_limit="251" upper_limit="334"/>
                    <measurement group_id="O8" value="248" lower_limit="227.5" upper_limit="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x1000/cubic mm)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="200.9" upper_limit="287"/>
                    <measurement group_id="O2" value="250.5" lower_limit="213.2" upper_limit="318"/>
                    <measurement group_id="O3" value="271" lower_limit="220" upper_limit="334"/>
                    <measurement group_id="O4" value="254" lower_limit="224" upper_limit="289"/>
                    <measurement group_id="O5" value="258" lower_limit="228" upper_limit="291"/>
                    <measurement group_id="O6" value="259" lower_limit="230" upper_limit="290"/>
                    <measurement group_id="O7" value="260" lower_limit="232" upper_limit="292"/>
                    <measurement group_id="O8" value="262.75" lower_limit="218" upper_limit="284.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x1000/cubic mm)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.5" lower_limit="198.5" upper_limit="276"/>
                    <measurement group_id="O2" value="265.9" lower_limit="224" upper_limit="309"/>
                    <measurement group_id="O3" value="269.5" lower_limit="230" upper_limit="324"/>
                    <measurement group_id="O4" value="256.2" lower_limit="232" upper_limit="288"/>
                    <measurement group_id="O5" value="284" lower_limit="240" upper_limit="327"/>
                    <measurement group_id="O6" value="276" lower_limit="244" upper_limit="306"/>
                    <measurement group_id="O7" value="279" lower_limit="246" upper_limit="315"/>
                    <measurement group_id="O8" value="257.5" lower_limit="237.5" upper_limit="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Participants With Grade 1 or Higher Local Laboratory Results.</title>
        <description>The numbers (percentages) of participants with local laboratory values recorded as meeting Grade 1 AE criteria or above as specified in the DAIDS AE Grading Table were tabulated by treatment group for each post vaccination timepoint.</description>
        <time_frame>Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Participants With Grade 1 or Higher Local Laboratory Results.</title>
          <description>The numbers (percentages) of participants with local laboratory values recorded as meeting Grade 1 AE criteria or above as specified in the DAIDS AE Grading Table were tabulated by treatment group for each post vaccination timepoint.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocytes (cells/cubic mm)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x1000/cubic mm)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)-Day 182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Positive Response Rates.</title>
        <description>IgG binding antibody breadth assays were not run. Instead, IgG was assayed against a smaller panel of antigens. Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Positive Response Rates.</title>
          <description>IgG binding antibody breadth assays were not run. Instead, IgG was assayed against a smaller panel of antigens. Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>00MSA 4076 gp140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1086C_D7gp120.avi/293F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96ZM651.gp140C.avi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1.con.env03 140 CF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Con 6 gp120/B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Con S gp140 CFI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Magnitudes.</title>
        <description>IgG binding antibody breadth assays were not run. Instead, IgG was assayed against a smaller panel of antigens.Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Magnitudes.</title>
          <description>IgG binding antibody breadth assays were not run. Instead, IgG was assayed against a smaller panel of antigens.Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
          <units>relative fluorescence units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>00MSA 4076 gp140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22000" lower_limit="11213.5" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="15544.625" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="14452.5" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="21484.5" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1086C_D7gp120.avi/293F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96ZM651.gp140C.avi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21251" lower_limit="11922.5" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="21760.75" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="17409.5" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1.con.env03 140 CF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22000" lower_limit="15131.25" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="20624.625" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="15995.5" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="13013" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="19209.125" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Con 6 gp120/B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22000" lower_limit="10550" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="18086.25" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="16341.75" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="20235.75" upper_limit="22000"/>
                    <measurement group_id="O8" value="9.75" lower_limit="1" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Con S gp140 CFI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Responses - Positive Response Rates.</title>
        <description>Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Responses - Positive Response Rates.</title>
          <description>Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TV1c8_D11gp120.avi/293F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gp70-TV1.GSKvacV1V2/293F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gp70_B.CaseA_V1_V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Response - Magnitudes.</title>
        <description>Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Response - Magnitudes.</title>
          <description>Serum IgG responses were measured on a Bio-Plex instrument using a custom Luminex assay, run at 1:50 dilution. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen minus reference antigen MFI. Net MFI below 1 is set to 1, and Net MFI above 22,000 is set to 22,000. Samples from post-baseline visits have positive responses if they meet three criteria: (1) net MFI &gt;= antigen-specific threshold (defined as the maximum of 100 and the 95th percentile of baseline net MFI), (2) net MFI &gt; 3 times baseline net MFI, and (3) experimental antigen MFI &gt; 3 times baseline MFI. Data are excluded if the blood draw date was outside the allowable window, a participant was HIV-infected, or the reference antigen exceeds 5000 MFI.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available BAMA data after filtering for assay specific quality control criteria.</population>
          <units>relative fluorescence units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TV1c8_D11gp120.avi/293F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O2" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O3" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O4" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O5" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O6" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O7" value="22000" lower_limit="22000" upper_limit="22000"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="26.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gp70-TV1.GSKvacV1V2/293F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="521.5" lower_limit="113.75" upper_limit="6977.75"/>
                    <measurement group_id="O2" value="1656" lower_limit="136" upper_limit="11641.600001"/>
                    <measurement group_id="O3" value="330" lower_limit="1" upper_limit="1337.25"/>
                    <measurement group_id="O4" value="4948.75" lower_limit="1574.25" upper_limit="11707.75"/>
                    <measurement group_id="O5" value="16511.5" lower_limit="2093" upper_limit="22000"/>
                    <measurement group_id="O6" value="10392.25" lower_limit="1706.5" upper_limit="22000"/>
                    <measurement group_id="O7" value="2409" lower_limit="317.125" upper_limit="16400.5"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gp70_B.CaseA_V1_V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744.5" lower_limit="148.75" upper_limit="7460.75"/>
                    <measurement group_id="O2" value="1110.625" lower_limit="86.125" upper_limit="7316.5"/>
                    <measurement group_id="O3" value="184.5" lower_limit="1" upper_limit="1269.75"/>
                    <measurement group_id="O4" value="1881" lower_limit="589" upper_limit="6311"/>
                    <measurement group_id="O5" value="5559" lower_limit="1255" upper_limit="18096.5"/>
                    <measurement group_id="O6" value="5231.875" lower_limit="1003.5" upper_limit="10415.25"/>
                    <measurement group_id="O7" value="1329.625" lower_limit="179.625" upper_limit="8718"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of Neutralizing Antibody Responses Against HIV-1 Isolates.</title>
        <description>The neutralizing antibody assay was not run. Therefore this dataset doesn't exist</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of Neutralizing Antibody Responses Against HIV-1 Isolates.</title>
          <description>The neutralizing antibody assay was not run. Therefore this dataset doesn't exist</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of HIV-specific CD4+ T-cell Responses - Positive Response Rates.</title>
        <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of HIV-specific CD4+ T-cell Responses - Positive Response Rates.</title>
          <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY HIV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY ENV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY POL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-1-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="26"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-2-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gag-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nef-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-1-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-2-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TV1 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1086 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of HIV-specific CD4+ T-cell Responses - Magnitudes.</title>
        <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of HIV-specific CD4+ T-cell Responses - Magnitudes.</title>
          <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
          <units>percent T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY HIV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.237" lower_limit="0.084" upper_limit="0.437"/>
                    <measurement group_id="O2" value="0.388" lower_limit="0.245" upper_limit="0.521"/>
                    <measurement group_id="O3" value="0.492" lower_limit="0.334" upper_limit="0.827"/>
                    <measurement group_id="O4" value="0.156" lower_limit="0.06" upper_limit="0.253"/>
                    <measurement group_id="O5" value="0.364" lower_limit="0.187" upper_limit="0.495"/>
                    <measurement group_id="O6" value="0.48" lower_limit="0.334" upper_limit="0.681"/>
                    <measurement group_id="O7" value="0.52" lower_limit="0.209" upper_limit="0.69"/>
                    <measurement group_id="O8" value="0.016" lower_limit="-0.013" upper_limit="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY ENV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" lower_limit="0.076" upper_limit="0.332"/>
                    <measurement group_id="O2" value="0.37" lower_limit="0.228" upper_limit="0.485"/>
                    <measurement group_id="O3" value="0.451" lower_limit="0.334" upper_limit="0.829"/>
                    <measurement group_id="O4" value="0.124" lower_limit="0.054" upper_limit="0.227"/>
                    <measurement group_id="O5" value="0.328" lower_limit="0.167" upper_limit="0.484"/>
                    <measurement group_id="O6" value="0.456" lower_limit="0.357" upper_limit="0.65"/>
                    <measurement group_id="O7" value="0.504" lower_limit="0.202" upper_limit="0.741"/>
                    <measurement group_id="O8" value="0.015" lower_limit="0.006" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY POL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="-0.009" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.011" upper_limit="0.007"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.016" upper_limit="0.01"/>
                    <measurement group_id="O4" value="0.003" lower_limit="-0.008" upper_limit="0.01"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.009" upper_limit="0.011"/>
                    <measurement group_id="O6" value="-0.002" lower_limit="-0.017" upper_limit="0.01"/>
                    <measurement group_id="O7" value="-0.002" lower_limit="-0.01" upper_limit="0.005"/>
                    <measurement group_id="O8" value="0.001" lower_limit="-0.009" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-1-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" lower_limit="0.038" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.196" lower_limit="0.117" upper_limit="0.305"/>
                    <measurement group_id="O3" value="0.272" lower_limit="0.14" upper_limit="0.445"/>
                    <measurement group_id="O4" value="0.038" lower_limit="0.021" upper_limit="0.072"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.054" upper_limit="0.155"/>
                    <measurement group_id="O6" value="0.186" lower_limit="0.092" upper_limit="0.261"/>
                    <measurement group_id="O7" value="0.092" lower_limit="0.033" upper_limit="0.232"/>
                    <measurement group_id="O8" value="0.008" lower_limit="-0.001" upper_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-2-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" lower_limit="0.016" upper_limit="0.104"/>
                    <measurement group_id="O2" value="0.052" lower_limit="0.031" upper_limit="0.088"/>
                    <measurement group_id="O3" value="0.085" lower_limit="0.038" upper_limit="0.161"/>
                    <measurement group_id="O4" value="0.02" lower_limit="0.009" upper_limit="0.025"/>
                    <measurement group_id="O5" value="0.04" lower_limit="0.015" upper_limit="0.108"/>
                    <measurement group_id="O6" value="0.054" lower_limit="0.019" upper_limit="0.095"/>
                    <measurement group_id="O7" value="0.045" lower_limit="0.015" upper_limit="0.097"/>
                    <measurement group_id="O8" value="0" lower_limit="-0.004" upper_limit="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gag-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" lower_limit="0.013" upper_limit="0.066"/>
                    <measurement group_id="O2" value="0.027" lower_limit="0.014" upper_limit="0.05"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0.013" upper_limit="0.054"/>
                    <measurement group_id="O4" value="0.016" lower_limit="0.011" upper_limit="0.022"/>
                    <measurement group_id="O5" value="0.011" lower_limit="0.001" upper_limit="0.025"/>
                    <measurement group_id="O6" value="0.013" lower_limit="0.006" upper_limit="0.045"/>
                    <measurement group_id="O7" value="-0.002" lower_limit="-0.009" upper_limit="0.009"/>
                    <measurement group_id="O8" value="0.001" lower_limit="-0.006" upper_limit="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nef-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.005" upper_limit="0.003"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.008" upper_limit="0.003"/>
                    <measurement group_id="O3" value="-0.002" lower_limit="-0.014" upper_limit="0.004"/>
                    <measurement group_id="O4" value="0" lower_limit="-0.006" upper_limit="0.003"/>
                    <measurement group_id="O5" value="-0.004" lower_limit="-0.01" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.012" upper_limit="0.004"/>
                    <measurement group_id="O7" value="-0.001" lower_limit="-0.009" upper_limit="0.007"/>
                    <measurement group_id="O8" value="-0.002" lower_limit="-0.008" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-1-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.005" upper_limit="0.004"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.007" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.007" upper_limit="0.005"/>
                    <measurement group_id="O4" value="0.001" lower_limit="-0.004" upper_limit="0.008"/>
                    <measurement group_id="O5" value="0.001" lower_limit="-0.006" upper_limit="0.005"/>
                    <measurement group_id="O6" value="0" lower_limit="-0.007" upper_limit="0.004"/>
                    <measurement group_id="O7" value="-0.001" lower_limit="-0.006" upper_limit="0.003"/>
                    <measurement group_id="O8" value="-0.001" lower_limit="-0.005" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-2-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" lower_limit="-0.006" upper_limit="0.008"/>
                    <measurement group_id="O2" value="-0.002" lower_limit="-0.008" upper_limit="0.005"/>
                    <measurement group_id="O3" value="-0.001" lower_limit="-0.012" upper_limit="0.009"/>
                    <measurement group_id="O4" value="0.001" lower_limit="-0.004" upper_limit="0.006"/>
                    <measurement group_id="O5" value="-0.002" lower_limit="-0.009" upper_limit="0.006"/>
                    <measurement group_id="O6" value="-0.003" lower_limit="-0.008" upper_limit="0.006"/>
                    <measurement group_id="O7" value="-0.001" lower_limit="-0.005" upper_limit="0.006"/>
                    <measurement group_id="O8" value="0.001" lower_limit="-0.005" upper_limit="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TV1 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" lower_limit="0.049" upper_limit="0.309"/>
                    <measurement group_id="O2" value="0.349" lower_limit="0.193" upper_limit="0.47"/>
                    <measurement group_id="O3" value="0.319" lower_limit="0.215" upper_limit="0.625"/>
                    <measurement group_id="O4" value="0.096" lower_limit="0.041" upper_limit="0.227"/>
                    <measurement group_id="O5" value="0.271" lower_limit="0.152" upper_limit="0.421"/>
                    <measurement group_id="O6" value="0.376" lower_limit="0.284" upper_limit="0.504"/>
                    <measurement group_id="O7" value="0.334" lower_limit="0.201" upper_limit="0.578"/>
                    <measurement group_id="O8" value="-0.003" lower_limit="-0.008" upper_limit="-0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1086 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.123" lower_limit="0.037" upper_limit="0.278"/>
                    <measurement group_id="O2" value="0.308" lower_limit="0.159" upper_limit="0.373"/>
                    <measurement group_id="O3" value="0.448" lower_limit="0.272" upper_limit="0.751"/>
                    <measurement group_id="O4" value="0.078" lower_limit="0.029" upper_limit="0.135"/>
                    <measurement group_id="O5" value="0.241" lower_limit="0.116" upper_limit="0.393"/>
                    <measurement group_id="O6" value="0.412" lower_limit="0.273" upper_limit="0.566"/>
                    <measurement group_id="O7" value="0.42" lower_limit="0.132" upper_limit="0.651"/>
                    <measurement group_id="O8" value="-0.001" lower_limit="-0.006" upper_limit="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of HIV-specific CD8+ T-cell Responses - Positive Response Rates.</title>
        <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of HIV-specific CD8+ T-cell Responses - Positive Response Rates.</title>
          <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY HIV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY ENV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY POL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-1-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-2-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gag-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nef-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-1-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-2-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TV1 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1086 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence and Level of HIV-specific CD8+ T-cell Responses - Magnitudes.</title>
        <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
        <time_frame>Measured at Month 6.5</time_frame>
        <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
            <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Placebo + Protein/AS01B</title>
            <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.&#xD;
Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.&#xD;
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
          <group group_id="O8">
            <title>Group 8: Placebo</title>
            <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.&#xD;
Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Level of HIV-specific CD8+ T-cell Responses - Magnitudes.</title>
          <description>PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. A contingency table is constructed to assess response: stimulation (peptide/none) vs. marker expression (yes/no). A one-sided Fisher's exact test is applied, testing if the number of cells positive for the marker is equal in the stimulated vs. unstimulated cells. A discrete Bonferroni adjustment is made over the peptide pools. Response is positive if p&lt;=0.00001. Any Env magnitude is the maximum of gp120 and Env ZM96 magnitude; Any Pol is the sum of CN54 magnitude; and Any HIV is the sum of Gag ZM96, Nef CN54, Any Pol, and Any Env. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.</description>
          <population>In this report, the &quot;overall number of participants analyzed&quot; represents the HIV uninfected participants with specimens at Month6.5. The &quot;Number Analyzed&quot; in the Outcome Measure Data Table shows the number of participants with available ICS data after filtering for assay specific quality control criteria.</population>
          <units>percent T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY HIV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="-0.004" upper_limit="0.035"/>
                    <measurement group_id="O2" value="0.019" lower_limit="-0.001" upper_limit="0.042"/>
                    <measurement group_id="O3" value="0.026" lower_limit="0.007" upper_limit="0.062"/>
                    <measurement group_id="O4" value="0.012" lower_limit="-0.004" upper_limit="0.021"/>
                    <measurement group_id="O5" value="0.019" lower_limit="0.001" upper_limit="0.043"/>
                    <measurement group_id="O6" value="0.006" lower_limit="-0.002" upper_limit="0.044"/>
                    <measurement group_id="O7" value="0.013" lower_limit="0.002" upper_limit="0.044"/>
                    <measurement group_id="O8" value="-0.004" lower_limit="-0.011" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY ENV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" lower_limit="-0.001" upper_limit="0.014"/>
                    <measurement group_id="O2" value="0.011" lower_limit="0.003" upper_limit="0.019"/>
                    <measurement group_id="O3" value="0.013" lower_limit="0.004" upper_limit="0.037"/>
                    <measurement group_id="O4" value="0.01" lower_limit="0.003" upper_limit="0.021"/>
                    <measurement group_id="O5" value="0.008" lower_limit="0.002" upper_limit="0.032"/>
                    <measurement group_id="O6" value="0.009" lower_limit="0.005" upper_limit="0.022"/>
                    <measurement group_id="O7" value="0.009" lower_limit="0.003" upper_limit="0.02"/>
                    <measurement group_id="O8" value="0.004" lower_limit="-0.001" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY POL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" lower_limit="-0.006" upper_limit="0.001"/>
                    <measurement group_id="O2" value="0.002" lower_limit="-0.005" upper_limit="0.013"/>
                    <measurement group_id="O3" value="0.002" lower_limit="-0.006" upper_limit="0.01"/>
                    <measurement group_id="O4" value="-0.001" lower_limit="-0.007" upper_limit="0.003"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.005" upper_limit="0.005"/>
                    <measurement group_id="O6" value="0" lower_limit="-0.009" upper_limit="0.006"/>
                    <measurement group_id="O7" value="0" lower_limit="-0.004" upper_limit="0.007"/>
                    <measurement group_id="O8" value="-0.005" lower_limit="-0.011" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-1-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" lower_limit="-0.005" upper_limit="0.002"/>
                    <measurement group_id="O2" value="0.003" lower_limit="-0.003" upper_limit="0.01"/>
                    <measurement group_id="O3" value="0.002" lower_limit="-0.003" upper_limit="0.01"/>
                    <measurement group_id="O4" value="0.001" lower_limit="-0.005" upper_limit="0.005"/>
                    <measurement group_id="O5" value="0.005" lower_limit="-0.002" upper_limit="0.014"/>
                    <measurement group_id="O6" value="0.005" lower_limit="0" upper_limit="0.015"/>
                    <measurement group_id="O7" value="0.006" lower_limit="0.002" upper_limit="0.012"/>
                    <measurement group_id="O8" value="-0.003" lower_limit="-0.006" upper_limit="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Env-2-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.002" upper_limit="0.005"/>
                    <measurement group_id="O2" value="0.002" lower_limit="-0.003" upper_limit="0.007"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.003" upper_limit="0.007"/>
                    <measurement group_id="O4" value="0.005" lower_limit="0" upper_limit="0.01"/>
                    <measurement group_id="O5" value="0" lower_limit="-0.003" upper_limit="0.007"/>
                    <measurement group_id="O6" value="-0.002" lower_limit="-0.004" upper_limit="0.008"/>
                    <measurement group_id="O7" value="0" lower_limit="-0.004" upper_limit="0.006"/>
                    <measurement group_id="O8" value="-0.002" lower_limit="-0.005" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gag-ZM96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="-0.002" upper_limit="0.007"/>
                    <measurement group_id="O2" value="0.001" lower_limit="-0.003" upper_limit="0.006"/>
                    <measurement group_id="O3" value="0.003" lower_limit="0" upper_limit="0.011"/>
                    <measurement group_id="O4" value="0" lower_limit="-0.003" upper_limit="0.004"/>
                    <measurement group_id="O5" value="0.002" lower_limit="-0.002" upper_limit="0.006"/>
                    <measurement group_id="O6" value="0.001" lower_limit="-0.002" upper_limit="0.01"/>
                    <measurement group_id="O7" value="0.002" lower_limit="-0.003" upper_limit="0.007"/>
                    <measurement group_id="O8" value="-0.001" lower_limit="-0.004" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nef-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.004" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.004" upper_limit="0.005"/>
                    <measurement group_id="O3" value="0.001" lower_limit="-0.005" upper_limit="0.005"/>
                    <measurement group_id="O4" value="0" lower_limit="-0.003" upper_limit="0.003"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.005" upper_limit="0.004"/>
                    <measurement group_id="O6" value="-0.002" lower_limit="-0.005" upper_limit="0.001"/>
                    <measurement group_id="O7" value="-0.001" lower_limit="-0.004" upper_limit="0.006"/>
                    <measurement group_id="O8" value="-0.003" lower_limit="-0.006" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-1-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.004" upper_limit="0"/>
                    <measurement group_id="O2" value="0.001" lower_limit="-0.003" upper_limit="0.003"/>
                    <measurement group_id="O3" value="0.002" lower_limit="-0.004" upper_limit="0.006"/>
                    <measurement group_id="O4" value="-0.002" lower_limit="-0.004" upper_limit="0.002"/>
                    <measurement group_id="O5" value="0" lower_limit="-0.003" upper_limit="0.002"/>
                    <measurement group_id="O6" value="0" lower_limit="-0.004" upper_limit="0.004"/>
                    <measurement group_id="O7" value="0.001" lower_limit="-0.002" upper_limit="0.004"/>
                    <measurement group_id="O8" value="0" lower_limit="-0.005" upper_limit="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pol-2-CN54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.003" upper_limit="0.001"/>
                    <measurement group_id="O2" value="0.001" lower_limit="-0.002" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0.001" lower_limit="-0.003" upper_limit="0.005"/>
                    <measurement group_id="O4" value="0" lower_limit="-0.005" upper_limit="0.004"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.005" upper_limit="0.003"/>
                    <measurement group_id="O6" value="0" lower_limit="-0.007" upper_limit="0.003"/>
                    <measurement group_id="O7" value="0" lower_limit="-0.003" upper_limit="0.005"/>
                    <measurement group_id="O8" value="-0.003" lower_limit="-0.005" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TV1 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.005" upper_limit="0.004"/>
                    <measurement group_id="O2" value="0.002" lower_limit="-0.004" upper_limit="0.007"/>
                    <measurement group_id="O3" value="0.002" lower_limit="-0.005" upper_limit="0.008"/>
                    <measurement group_id="O4" value="0.001" lower_limit="-0.004" upper_limit="0.006"/>
                    <measurement group_id="O5" value="0.003" lower_limit="-0.003" upper_limit="0.012"/>
                    <measurement group_id="O6" value="0.003" lower_limit="-0.003" upper_limit="0.009"/>
                    <measurement group_id="O7" value="0.001" lower_limit="-0.002" upper_limit="0.004"/>
                    <measurement group_id="O8" value="0" lower_limit="-0.005" upper_limit="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1086 gp120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="-0.002" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.002" lower_limit="-0.003" upper_limit="0.01"/>
                    <measurement group_id="O3" value="0.002" lower_limit="-0.004" upper_limit="0.014"/>
                    <measurement group_id="O4" value="0.005" lower_limit="-0.002" upper_limit="0.013"/>
                    <measurement group_id="O5" value="0.001" lower_limit="-0.003" upper_limit="0.014"/>
                    <measurement group_id="O6" value="0.001" lower_limit="-0.003" upper_limit="0.009"/>
                    <measurement group_id="O7" value="0" lower_limit="-0.004" upper_limit="0.009"/>
                    <measurement group_id="O8" value="-0.001" lower_limit="-0.006" upper_limit="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events and new chronic conditions requiring medical intervention of more than 30 days were collected through the month 12 timepoint. Adverse events of special interest were collected through month 18. All other AEs were collected through 30 days after each vaccination.</time_frame>
      <desc>Adverse events of special interest were described in the protocol Appendix J. AESI for this protocol include but are not limited to potential immune-mediated diseases.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/MF59 vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E6">
          <title>Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B</title>
          <description>Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. DNA-HIV-PT123 vaccine: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E7">
          <title>Group 7: Placebo + Protein/AS01B</title>
          <description>Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3. Bivalent Subtype C gp120/AS01B vaccine: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose. Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
        <group group_id="E8">
          <title>Group 8: Placebo</title>
          <description>Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6. Placebo: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E3" events="32" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E5" events="24" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E6" events="23" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E7" events="15" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E8" events="10" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Genitourinary tract gonococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mycetoma mycotic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Proctitis chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginitis chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chemical burn of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E5" events="22" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E6" events="16" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E7" events="9" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="9" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alcoholic hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Attention deficit hyperactivity disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Any SOC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica Andriesen, PhD, Associate Director of HVTN SDMC Operations</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-5812</phone>
      <email>jandries@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

